HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDE requested for "self-growing" heart valve:

This article was originally published in Clinica

Executive Summary

CryoLife has submitted an investigational device exemption (IDE) application to the FDA to begin US trials of its SynerGraft tissue-engineered pulmonary heart valve, intended for children. The product is a collagen frame based on a porcine valve from which the cells have been removed. Animal studies show that the frame is re-populated by the recipient's own cells and grows as the recipient grows. Six Australian adults already have SynerGraft implants and all are "doing well", says the Atlanta, Georgia-based company. It hopes the US trials will recruit up to 150 pediatric patients. Meanwhile European regulators are considering the product for CE-marking, the company claims.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel